KRAS Mutation Is Associated With Elevated Myeloblastin Activity In Human Lung Adenocarcinoma
作者： Sven Hillinger , Thomas Wiedl , Stephane Collaud , Stephan Arni , Peter Schraml
DOI: 10.1164/AJRCCM-CONFERENCE.2012.185.1_MEETINGABSTRACTS.A6360
关键词:
摘要: Lung cancer is the leading cause of all deaths worldwide with suboptimal prognosis and treatment options. Therefore this study aimed to identify molecular characteristics a predictive clinical utility which at same time might represent novel therapeutic targets for human lung adenocarcinoma. Within mutations v-Ki-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS), gene frequently mutated in adenocarcinoma, their association enzymatic activities, as assessed by activity-based proteomics, members serine hydrolase (SH) superfamily, large class enzymes that have previously been linked was investigated. The results revealed activity myeloblastin significantly altered adenocarcinoma biopsies harboring KRAS mutation. In conclusion potential target indicating combination proteomics mutational analysis valid approach discovery biomarkers.
uzh.ch
sci-hub.st 参考文章(13)
Marisa Pearce, Amy Cullinan, Grant Hogg, Dana Hosseini, Mathias Ehrich, Mutation profiling in tumor samples using the Sequenom OncoCarta|[trade]| Panel Nature Methods. ,vol. 6, ,(2009) , 10.1038/NMETH.F.254
C OWEN, Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization. The International Journal of Biochemistry & Cell Biology. ,vol. 40, pp. 1246- 1272 ,(2008) , 10.1016/J.BIOCEL.2008.01.020
T. Wiedl, S. Arni, B. Roschitzki, J. Grossmann, S. Collaud, A. Soltermann, S. Hillinger, R. Aebersold, W. Weder, Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. Journal of Proteomics. ,vol. 74, pp. 1884- 1894 ,(2011) , 10.1016/J.JPROT.2011.04.030
Ganesh V. Sangle, Ruozhi Zhao, Tooru M. Mizuno, Garry X. Shen, Involvement of RAGE, NADPH oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Endocrinology. ,vol. 151, pp. 4455- 4466 ,(2010) , 10.1210/EN.2010-0323
Richard F Schlenk, Konstanze Döhner, Jürgen Krauter, Stefan Fröhling, Andrea Corbacioglu, Lars Bullinger, Marianne Habdank, Daniela Späth, Michael Morgan, Axel Benner, Brigitte Schlegelberger, Gerhard Heil, Arnold Ganser, Hartmut Döhner, None, Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia The New England Journal of Medicine. ,vol. 358, pp. 1909- 1918 ,(2008) , 10.1056/NEJMOA074306
James D. Webb, M. Celeste Simon, Novel insights into the molecular origins and treatment of lung cancer. Cell Cycle. ,vol. 9, pp. 4098- 4105 ,(2010) , 10.4161/CC.9.20.13588
M.C. Garassino, M. Marabese, P. Rusconi, E. Rulli, O. Martelli, G. Farina, A. Scanni, M. Broggini, Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer Annals of Oncology. ,vol. 22, pp. 235- 237 ,(2011) , 10.1093/ANNONC/MDQ680
Dominique Bories, Marie-Cecile Raynal, David H. Solomon, Zbigniew Darzynkiewicz, Yvon E. Cayre, Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells Cell. ,vol. 59, pp. 959- 968 ,(1989) , 10.1016/0092-8674(89)90752-6
Patrick J. Roberts, Thomas E. Stinchcombe, Channing J. Der, Mark A. Socinski, Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy? Journal of Clinical Oncology. ,vol. 28, pp. 4769- 4777 ,(2010) , 10.1200/JCO.2009.27.4365
Nadim Jessani, Sherry Niessen, BinQing Q Wei, Monica Nicolau, Mark Humphrey, Youngran Ji, Wonshik Han, Dong-Young Noh, John R Yates, Stefanie S Jeffrey, Benjamin F Cravatt, A streamlined platform for high-content functional proteomics of primary human specimens Nature Methods. ,vol. 2, pp. 691- 697 ,(2005) , 10.1038/NMETH778